Skip to main content
Canna~Fangled Abstracts

Human laryngeal squamous cell carcinoma cell line release of endogenous anandamide and 2-arachidonoylglycerol, and their antiproliferative effect via exogenous supplementation: an in vitro study

By April 2, 2021No Comments
Thus, cannabinoid ligands might represent novel drug candidates for laryngeal cancers, although functional in vivo studies are required in order to validate their potency.
. 2021 Apr 2.

doi: 10.1007/s10561-021-09917-9.

Online ahead of print.
Övsen Önay 1, Sevil Köse 2, Nilda Süslü 3, Petek Korkusuz 4, Emirhan Nemutlu 5, Canset Aydın 6, Şefik Hoşal 7
Affiliations 

Abstract

The level of the major endocannabinoids anandamide (AEA) and 2-arachidonoylglycerol (2-AG) are altered in several types of carcinomas, and are known to regulate tumor growth. Thusly, this study hypothesized that the HEp-2 human laryngeal squamous cell carcinoma (LSCC) cell line releases AEA and 2-AG, and aimed to determine if their exogenous supplementation has an anti-proliferative effect in vitro. In this in vitro observational study a commercial human LSCC cell line (HEp-2) was used to test for endogenous AEA and 2-AG release via liquid chromatography-tandem mass spectrometry (LC-MS/MS). The anti-proliferative effect of AEA and 2-AG supplementation was evaluated via WST-1 proliferation assay. It was observed that the HEp-2 LSCC cell line released AEA and 2-AG; the median quantity of AEA released was 15.69 ng mL-1 (range: 14.55-15.95 ng mL-1) and the median quantity of 2-AG released was 2.72 ng -1 (range: 2.67-2.74 ng mL-1). Additionally, both AEA and 2-AG exhibited an anti-proliferative effect. The anti-proliferative effect of 2-AG was stronger than that of AEA. These findings suggest that AEA might function via a CB1 receptor-independent pathway and that 2-AG might function via a CB2-dependent pathway. The present findings show that the HEp-2 LSCC cell line releases the major endocannabinoids AEA and 2-AG, and that their supplementation inhibits tumor cell proliferation in vitro. Thus, cannabinoid ligands might represent novel drug candidates for laryngeal cancers, although functional in vivo studies are required in order to validate their potency.

 

Keywords: 2-Arachidonoylglycerol, Anandamide, Endocannabinoid, Laryngeal carcinoma

References

    1. Baird BJ, Sung CK, Beadle BM, Divi V (2018) Treatment of early-stage laryngeal cancer: a comparison of treatment options. Oral Oncol 87:8–16 – DOI
    1. Bisogno T, MacCarrone M, De Petrocellis L, Jarrahian A, Finazzi-Agro A, Hillard C, Di Marzo V (2001) The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors. Eur J Biochem 268(7):1982–1989 – DOI
    1. Bolognini D, Cascio MG, Parolaro D, Pertwee RG (2012) AM630 behaves as a protean ligand at the human cannabinoid CB2 receptor. Br J Pharmacol 165(8):2561–2574 – DOI
    1. Bozkurt TE (2019) Endocannabinoid system in the airways. Molecules 24(24):4626 – DOI
    1. Bradshaw HB, Rimmerman N, Krey JF, Walker JM (2006) Sex and hormonal cycle differences in rat brain levels of pain-related cannabimimetic lipid mediators. Am J Physiol Regul Integr Comp Physiol 291(2):R349-358 – DOI

Leave a Reply